BioVex Group has developed a virus-containing vaccine which works to prevent and combat certain types of cancer and chronic infectious diseases. The company's lead product, OncoVEX, makes use of an altered virus to attack solid tumor cells but leave healthy cells intact. OncoVEX has shown promise in treating metastatic melanoma and the company has plans to vex other cancers such as pancreatic and colo-rectal cancers. After a brief stint as a publicly-traded company, in 2007 BioVex was taken private by a group of investors led by health science-oriented Triathlon Medical Ventures.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

Babraham Bioscience Technologies (BBT) is the operating company of the Babraham Institute, which works with companies around the world on pharmaceutical and biotechnology research projects. The company is committed to fostering innovation and bridging the gap from research to daily application. Through Babraham Technix, the company provides financial and administrative services to start-up biotech companies. It gives special emphasis to companies emerging from its Babraham Bioincubator division, which supports companies that research the role of genomics in healthcare. Commercial spin-offs from BBT include Discerna Ltd. and Orla Protein Technologies.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human monoclonal antibodies (single-source proteins). Medarex has more than 40 antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, arthritis, and other conditions. Other development partners include Pfizer, Amgen, Eli Lilly, and Kirin. Another major collaborator, Bristol-Myers Squibb, acquired Medarex for $2.4 billion in 2009.

Teva Neuroscience, Inc. engages in the development, registration, and marketing of neurological products in North America. It offers COPAXONE, a glatiramer acetate injection that reduces relapses in people with relapsing-remitting multiple sclerosis; and AZILECT, a rasagiline tablet for the treatment of the signs and symptoms of Parkinson disease. Teva Neuroscience, Inc. was formerly known as Teva Marion Partners and changed its name to Teva Neuroscience, Inc. in February, 2001. Teva Neuroscience, Inc. was founded in 1995 and is based in Kansas City, Missouri with an additional office in Montreal, Canada. It has a facility in Horsham, Pennsylvania. As per the transaction announced on 2/14/2001, Teva Neuroscience, Inc. is a subsidiary of Teva Pharmaceutical Industries Limited.

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas. Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

Innovative work in genetic testing is apparently spelled Innogenetics in any language. The biopharmaceutical company creates genetic, infectious disease, cancer, and neurological tests. Innogenetics' products include tests and genotyping profiles to identify conditions such as cystic fibrosis, HIV, hepatitis C and B, Alzheimer's disease, and human papillomavirus (HPV). In addition to testing, the company provides biological manufacturing services (producing virus strains and proteins) for pharmaceutical firms and research labs. The firm's products are sold through subsidiaries and distributors in about 90 countries. Belgium's Solvay took over control of Innogenetics in 2008.

William Ransom & Son plc is a United Kingdom-based company engaged in the supply of branded natural health products, vitamins and food supplements, the manufacture of pharmaceutical products and the extraction of plant material for the pharmaceutical, food and beverage industries. The Company operates in three divisions: consumer healthcare, pharmaceutical and natural products. Consumer healthcare includes the sale of consumer-branded healthcare products. The pharmaceutical division includes the manufacture of its own Medicines and Healthcare Products Regulatory Agency (MHRA)-licensed products, as well as pharmaceuticals and over-the-counter products for third parties. The natural products division includes the manufacture of botanical extracts used as ingredients by the pharmaceutical division and sold to third parties.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.